Achaogen Inc (AKAO) 6.21 $AKAO Nasdaq stocks posting

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 7:59 PM

Achaogen Inc (AKAO) 6.21 $AKAO

Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 09, 5:15PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
GEOS: 20.76 (+0.57), FLML: 15.84 (-0.33), RECN: 16.46 (+0.14), SEV: 7.27 (-0.02), QURE: 26.15 (-1.44), FONR: 11.72 (+0.08), MARPS: 12.39 (+0.21), ANGI: 6.46 (+0.31), AKAO: 6.21 (-0.50), OCUL: 25.90 (-0.05), AREX: 8.15 (-0.30)

Achaogen to Present at 14th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 09, 4:30AM CDT
Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it will present at the 14th Annual Needham Healthcare Conference in New York, New York. Dr. Kenneth Hillan, Chief Executive Officer, will provide an update on the development plan for their lead program, plazomicin, which in addition to its ongoing Phase 3 trial in carbapenem-resistant Enterobacteriaceae (CRE), now includes a Phase 3 study in complicated urinary tract infections (cUTI) that Achaogen expects to serve as a pivotal study to support the filing of a New Drug Application with the US Food and Drug Administration. The presentation will take place on Wednesday, April 15th at 10:40 a.m. Eastern Time, at the Westin NY Grand Central Hotel.
AKAO: 6.21 (-0.50)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 11:45AM CDT

IMDZ: 26.66 (+0.22), UTIW: 9.39 (+0.07), VTNR: 2.41 (-0.03), SIEB: 1.77 (-0.13), OIBR: 2.07 (-0.04), AKAO: 6.21 (-0.50), EVRY: 0.18 (unch), MSB: 15.46 (+0.41), VLTC: 15.14 (-1.04), TRIL: 20.67 (-2.53), HKTV: 7.67 (-0.33), DYAX: 28.12 (+0.15), GBSN: 4.98 (+1.44), PRXI: 4.82 (+0.27), CTSO: 7.13 (-0.06), LIME: 2.85 (-0.12), SSP: 23.52 (+0.13), WLDN: 16.11 (-0.03), GDDY: 24.77 (-0.01), ERII: 3.22 (+0.09)

Achaogen slumps on longer-than-expected plazomicin timeline
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 9:13AM CDT

AKAO: 6.21 (-0.50)

Achaogen to update investors on lead program tomorrow
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 3:51PM CDT

AKAO: 6.21 (-0.50)

Achaogen Announces Webcast Providing Update on Development Plan for Plazomicin
GlobeNewswire - Mon Mar 30, 3:15PM CDT
Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, is pleased to host a webcast and teleconference providing an update on its lead program, plazomicin. The webcast and teleconference will take place on Tuesday, March 31 at 4:30PM Eastern Time where management will review its updated development plan for the program.
AKAO: 6.21 (-0.50)

Achaogen reports 4Q loss
Automated Insights - Mon Mar 16, 5:01PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Achaogen Inc. (AKAO) on Monday reported a loss of $4.9 million in its fourth quarter.
AKAO: 6.21 (-0.50)

Achaogen beats by $0.06, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 4:30PM CDT

AKAO: 6.21 (-0.50)

Achaogen Announces Fourth Quarter and Full Year 2014 Results
GlobeNewswire - Mon Mar 16, 3:20PM CDT
Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today reported financial results for the quarter and year ended December 31, 2014.
AKAO: 6.21 (-0.50)

Achaogen to Present at the Jefferies 2015 Antibiotic Summit on March 18, 2015
GlobeNewswire - Thu Mar 12, 3:30PM CDT
Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it will present at the Jefferies 2015 Antibiotic Summit in New York, New York. Kenneth Hillan, Chief Executive Officer, is scheduled to present on Wednesday, March 18at 3:10 p.m. Eastern Time.
AKAO: 6.21 (-0.50)

Achaogen Announces Appointment of Kent Lieginger and Alan Colowick to Board of Directors
GlobeNewswire - Thu Mar 12, 3:15PM CDT
Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today the appointments of Dr. Alan Colowick and Dr. Kent Lieginger to its Board of Directors. In conjunction with these appointments, Dr. Scott Rocklage and Camille Samuels resigned from Achaogen's Board of Directors effective March 20, 2015.
AKAO: 6.21 (-0.50)

Traders smitten with tiny thinly-traded biotechs
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 9:44AM CST

GENE: 4.88 (-0.05), HTBX: 7.71 (-0.64), SGNL: 2.21 (+0.02), ROSG: 3.83 (-0.20), TTPH: 39.96 (-0.50), ONCY: 0.80 (unch), CLRX: 0.95 (unch), MELA: 1.52 (-0.14), AKAO: 6.21 (-0.50), WGBS: 4.66 (-0.08), EGRX: 60.53 (+1.22)

Antibiotic developers up premarket on superbug exposure in Los Angeles
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 7:37AM CST

TTPH: 39.96 (-0.50), AKAO: 6.21 (-0.50)

Achaogen Announces Plazomicin Granted QIDP Designation by FDA
GlobeNewswire - Thu Jan 08, 4:30AM CST
Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today announced that the Company's lead product candidate, plazomicin, has received Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA). The QIDP designation was created by the Generating Antibiotic Incentives Now (GAIN) Act, which was part of the FDA Safety and Innovation Act (FDASIA) and provides certain incentives for the development of new antibiotics, including priority review and an additional five years of market exclusivity. The FDA granted fast track status for plazomicin in 2012.
AKAO: 6.21 (-0.50)

Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014
M2 - Wed Jan 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/2z3625/community) has announced the addition of the "Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Achaogen Inc. - Furiex Pharmaceuticals, Inc. - Galapagos NV - Novan, Inc. Drug Profiles - acorafloxacin - GLPG-1492 - NVN-4428 - SB-204 - Small Molecules to Inhibit Beta Lactamase for Bacterial Infections - Synthetic Peptide for Multi-Drug Resistant Bacterial Infections For more information visit http://www.researchandmarkets.com/research/2z3625/community
AKAO: 6.21 (-0.50)

Achaogen (AKAO) Crumbles: Stock Falls by 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 7:34AM CST
Achaogen (AKAO) fell by nearly 7% in the last trading session amid huge volumes, reversing its recent uptrend, as the stock is now up nearly 30% in the past one month.
AKAO: 6.21 (-0.50), BIOD: 1.24 (-0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...